Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

(2019) Kyung Hae Jung et al.   CLINICAL CANCER RESEARCH

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

(2018) Asha Nayak-Kapoor et al.   Journal for ImmunoTherapy of Cancer

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

(2018) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

(2015) Michael Platten et al.   Frontiers in Immunology

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

(2014) Mario R. Mautino et al.   CANCER RESEARCH

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

(2011) Jonathan R. Brody et al.   CELL CYCLE

Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival

(2008) K. Ino et al.   CLINICAL CANCER RESEARCH

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer

(2008) Chantal Feder-Mengus et al.   EUROPEAN JOURNAL OF CANCER

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

(2008) M. E.D. Chamuleau et al.   HAEMATOLOGICA

Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection

(2008) Agnes Witkiewicz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS